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Abstract
Background and aims: Innovative treatment modalities have not yet shown a clinical benefit in patients with
septic shock. To reduce severe cytokinaemia, CytoSorb as an add-on to continuous renal replacement therapy
(CRRT) showed promising results in case reports. However, there are no clinical trials investigating outcomes.
Methods: In this investigator-initiated retrospective study, patients with septic shock were treated with CRRT +
CytoSorb (n = 67) or CRRT alone (n = 49). The primary outcome was the 28-day all-cause mortality rate. Patients
were weighted by stabilized inverse probability of treatment weights (sIPTW) to overcome differences in baseline
characteristics.
Results: At the start of therapy, CytoSorb-treated patients had higher lactate levels (p < 0.001), lower mean arterial
pressure (p = 0.007) and higher levels of noradrenaline (p < 0.001) compared to the CRRT group. For CytoSorb, the
mean predicted mortality rate based on a SOFA of 13.8 (n = 67) was 75% (95%CI 71–79%), while the actual 28-day
mortality rate was 48% (mean difference − 27%, 95%CI − 38 to − 15%, p < 0.001). For CRRT, based on a SOFA of 12.8
(n = 49), the mean predicted versus observed mortality was 68% versus 51% (mean difference − 16.9% [95%CI −
32.6 to − 1.2%, p = 0.035]). By sIPTW analysis, patients treated with CytoSorb had a significantly lower 28-day
mortality rate compared to CRRT alone (53% vs. 72%, respectively, p = 0.038). Independent predictors of 28-day
mortality in the CytoSorb group were the presence of pneumosepsis (adjusted odds ratio [aOR] 5.47, p = 0.029),
higher levels of lactate at the start of CytoSorb (aOR 1.15, p = 0.031) and older age (aOR per 10 years 1.67, p = 0.034).
Conclusions: CytoSorb was associated with a decreased observed versus expected 28-day all-cause mortality. By
IPTW analysis, intervention with CytoSorb may be associated with a decreased all-cause mortality at 28 days
compared to CRRT alone.
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Introduction
Sepsis and septic shock are a major health burden
worldwide leading to approximately 5 million deaths an-
nually [1–3]. Although the reported incidence of sepsis
varies widely and is notoriously unreliable, it is the lead-
ing cause of mortality globally, and its incidence cur-
rently is thought to rise due to aging populations,
increasing comorbidity and greater recognition due to
increasing awareness of this disease over the past de-
cades [4, 5]. Septic shock is thought to arise from a dis-
rupted balance between pro-inflammatory and anti-
inflammatory cytokines in response to infection, ultim-
ately leading to cell and organ dysfunction [5]. Recent
advances in the field of sepsis treatment had variable
success, presumably because sepsis is a very heteroge-
neous disease entity and therefore resists a one-size-fits-
all approach. To date, only advancement in supportive
care, such as timely delivery of antibiotics and early fluid
resuscitation, has led to a significant improvement in the
outcome of sepsis [4]. Other treatment modalities, such
as continuous renal replacement therapy (CRRT) have
not shown clinical benefit, although it was shown that
cytokines such as tumour necrosis factor (TNF) α and
interleukin (IL) 1β could be cleared from serum [6–8].
Recently, CytoSorb has been developed and approved
in Europe since 2011 for use in patients with severe
cytokinaemia [9–11]. CytoSorb is a filter which can be
used in addition to continuous renal replacement ther-
apy (CRRT), and other devices such as hemodialysis,
heart-lung machines and extracorporeal membrane oxy-
genation. It is a non-pyrogetic, sterile single-use filter for
the removal of endotoxins and cytokines [10]. Since it is
able to reduce circulating cytokines such as IL-1β, TNF-
α, IL-6 and IL-10 by more than 90%, CytoSorb is
thought to have considerable impact on a derailed host
response causing shock [10, 12]. This treatment modality
has shown promising results in animal studies [13, 14]
and case reports [15–18]. Nevertheless, a recent ran-
domized trial in patients with septic shock and acute
lung injury (ALI) or acute respiratory distress syndrome
(ARDS) assessed, but was not powered for mortality,
and found no difference in clinical outcome [11, 19]. It
is therefore unknown whether CytoSorb leads to a sur-
vival benefit.
Hence, the aim of the current study is to investigate
whether the application of CytoSorb in addition to CRRT
leads to a reduction in 28-day mortality compared to CRRT
alone in patients with septic shock in the ICU, by using the
inversed probability of treatment weights method.
Patients and methods
Patients
In this retrospective investigator-initiated study, patients
admitted to the ICU of the Maasstad Hospital with
septic shock [5] treated with CRRT with or without
CytoSorb from Jan 01, 2014 - April 01, 2017, were ini-
tially eligible for inclusion. CytoSorb was initiated at the
discretion of the treating intensive care physician. Indi-
cations for CytoSorb therapy were age 18–80 years and
having a septic shock (see definitions below). Patients
were treated per protocol, agreed upon by the staff of in-
tensive care physicians. All patients in this study were
treated with CRRT. Patients were excluded from the
analysis in case the primary diagnosis was not septic
shock (out of hospital cardiac arrest, rhabdomyolysis,
intoxications, metabolic disturbances, kidney or heart
failure with type 1 respiratory insufficiency requiring
CRRT, or presence of active malignancy). Moreover,
CytoSorb or CRRT was discontinued in case shock or
renal function was improved. For the current study, to
test the application of CytoSorb to CRRT in a clinical
practice setting, there were no constraints to the timing
of admission to the ICU, the severity of septic shock at
the start of therapy and the eventual duration of therapy.
Patients were treated per protocol as part of standard of
care, i.e. no interventions were applied for the purpose
of this study, and data was collected retrospectively. Pa-
tients who initiated on CytoSorb subsequent to CRRT
were evaluated in the CytoSorb cohort. CytoSorb was
used according to the manufacturer’s protocol. It was
placed in a blood-pump circuit with an optimal ultrafil-
tration rate of 250–400 mL/min. The CytoSorb filter was
changed after 24 h of use.
Definitions
Septic shock was defined as a life-threatening organ
dysfunction caused by a dysregulated host response to
infection, identified by persisting hypotension requir-
ing vasopressive medication to maintain mean arterial
pressure (MAP) ≥ 65 mmHg and having a serum lac-
tate level > 2 mmol/L despite adequate volume resus-
citation [5]. Shock reversal was defined as a serum
lactate level ≤ 2 mmol/L and discontinuation of vaso-
pressive medication [20].
Endpoints
The primary endpoint was the 28-day all-cause mortality
compared for CytoSorb versus CRRT alone. Secondary
endpoints included the comparison between the ob-
served 28-day mortality rate in the CytoSorb treatment
group versus the predicted mortality according to the
SOFA score [21, 22], and variables that predict mortality
in the CytoSorb group. All-cause mortality was mea-
sured from ICU admission until 28 days after admission
(irrespective of ICU, in-hospital or out of hospital
mortality).
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Statistical analysis
For the first part, the predicted probability according to
the SOFA score at the start of therapy [21, 22] was calcu-
lated for each individual and compared with the observed
mortality rate in the CytoSorb group using a paired T-test.
For the second part, all evaluations were carried out using
the inverse probability of treatment weights (IPTW), in-
cluding a stabilizing method to avoid bias from extreme
weights [23, 24]. Stabilized IPTW (sIPTW) is applied to
overcome differences in baseline patient characteristics, to
mimic a randomized controlled trial. Weights are based on
the propensity score to create a synthetic sample in which
the baseline variables are independent of the treatment as-
signment. First, all variables in the dataset were tested for
their association with either CytoSorb or CRRT treatment.
From this analysis, factors associated with the treatment in
univariate analysis were selected to construct a multivari-
able model to estimate the probability of being treated with
CRRT or CytoSorb. Second, the probability of being treated
with CRRT or CytoSorb was estimated using the following
baseline factors in a logistic regression analysis: age, SOFA
score at the start of therapy, lactate level at the start of ther-
apy, dosage of vasopressive medication (in μg/kg/min) at
the start of therapy, known comorbidity, surgery just prior
to or during ICU admission and origin of sepsis. These fac-
tors are also associated with the primary outcome [5, 21,
25]. Third, patients were weighted by the inverse of this
propensity, which was stabilized prior to the analyses using
the estimated marginal means of the calculated propensity
[23]. The absolute standardized difference for variables be-
tween the two treatment groups were calculated using
Cohen’s D and graphically inspected (Additional file 1: Fig-
ure S1). The association between CytoSorb or CRRT with
clinical outcome at 28 days was then estimated by chi-
square analysis. Fourth, to account for variables still show-
ing imbalance after adjustment by sIPTW, multivariable lo-
gistic regression was applied using both the stabilized
weights and adjusting for unbalanced variables [24]. Factors
associated with 28-day mortality in CytoSorb-treated pa-
tients were analysed as well. For this, factors with a p value
< 0.1 in univariate analysis were considered for multivari-
able regression analyses. First, a full multivariable model
was constructed where all possible important variables were
forced into the model. Second, using the same variables
from the full model, the final model was constructed with
the backstep likelihood ratio method. SPSS version 22.0
(SPSS Inc., Chicago, IL, USA) was used to perform statis-
tical analyses. All statistical tests were two-sided and evalu-
ated at the 0.05 level of significance.
Results
Patient characteristics
In total, 210 patients were treated, of which 101 with
CytoSorb and 109 with CRRT only. Of the patients
treated with CytoSorb, 67 were treated because of septic
shock, versus 49 for CRRT. Figure 1 shows the patient
selection and reasons for exclusion. The patient charac-
teristics can be found in Table 1. It was observed that
patients treated with CytoSorb had worse hemodynamic
characteristics when compared to CRRT alone. Cyto-
Sorb-treated patients had higher lactate levels both at
admission (p = 0.027) and at the start of therapy (p <
0.001), were administered higher levels of noradrenaline
(p < 0.001) and had lower mean arterial pressure (p =
0.007). Patients were treated with CRRT for a mean dur-
ation of 4.96 (SE 0.63) days in the CRRT group and 4.97
(SE 0.55) days in the CytoSorb group (p = 0.990). In the
CytoSorb group, patients were treated with CytoSorb
added to CRRT for a mean duration of 2.34 (SE 0.16)
days and with CRRT only for a mean 2.66 (SE 0.52) days.
The mean duration from ICU admission to the start of
treatment was 2.1 (SE 0.36) versus 1.66 (SE 0.38) days
(p = 0.416) for CRRT versus CytoSorb, respectively. In
total, 88% (n = 59) patients commenced CytoSorb dir-
ectly together with CRRT because of septic shock (i.e.
no delay between CRRT and CytoSorb), 4 patients had a
delay in the start of CytoSorb after CRRT of 1 day and
another 4 had a delay of > 1 day. Moreover, the mean
duration from hospital admission to the start of treat-
ment did not differ between the groups (4.7 versus 3.8
days, p = 0.306). After adjustment with sIPTW, the
CRRT and CytoSorb groups were largely comparable
(Table 1 and Additional file 1: Figure S1).
CytoSorb treatment: observed versus predicted 28-day
mortality
When no correction for baseline variables was applied, it
was shown that the 28-day all-cause mortality rate was
similar for CytoSorb versus CRRT (47.8% versus 51.0%,
p = 0.729, Fig. 2). For the CytoSorb group, the mean
SOFA score at the start of therapy was 13.8 (SE 2.8), and
the delta SOFA score (admission to treatment) was 2.1
(SE 0.41). On the basis of the SOFA score, the mean
predicted mortality rate was 74.5% (95%CI 70.7–79.0%)
[21], while the actual 28-day mortality rate was 47.8%
(95%CI 35.7–59.8%), corresponding to a mean difference
of − 26.8% (95%CI − 38.2 to − 15.3%, p < 0.001). For the
CRRT only group, the mean SOFA score was 12.8 (SE
3.2), corresponding to a mean predicted mortality rate of
67.9% (95%CI 60.7–75.2%), while the observed mortality
rate was 51.0% (95%CI 36.9–65.2%) with a mean differ-
ence − 16.9% (95%CI − 32.6 to − 1.2%, p = 0.035).
CytoSorb is associated with a reduced 28-day mortality:
sIPTW analysis
By sIPTW chi-square analysis, the 28-day mortality sig-
nificantly differed for CytoSorb versus CRRT: 53.0% ver-
sus 72.3%, respectively (p = 0.038, Fig. 2). By sIPTW
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multivariable analysis additionally adjusted for MAP
and chronic kidney disease (CKD), CytoSorb treatment
was also significantly associated with an improved 28-
day outcome (OR 0.37, 95% confidence interval [CI]
0.15–0.92, p = 0.032). In this analysis, CKD was not as-
sociated with 28-day mortality (OR 1.93, 95%CI 0.69–
5.44, p = 0.214), and a higher MAP was associated with
a lower chance of mortality (OR 0.95, 95%CI 0.92–0.98,
p = 0.003).
Factors associated with 28-day mortality for CytoSorb
therapy
Factors at the start of therapy significantly associated
with mortality at 28 days for CytoSorb-treated patients
were the SOFA score (OR 1.28, 95%CI 1.05–1.56, p =
0.014), lactate levels (OR 1.16, 95%CI 1.03–1.30, p =
0.014), noradrenaline levels (OR 2.60, 95%CI 1.15–5.87,
p = 0.021), and older age (OR 1.67 per 10 years older,
p = 0.002, Table 2). For patients with mortality versus
those who survived, initiation of CytoSorb was 1.13 (SE
0.35) versus 2.14 (SE 0.65) days, respectively (p = 0.18).
To investigate whether CytoSorb treatment may have
been initiated earlier in patients with worse septic shock,
interactions between therapy timing and lactate levels or
SOFA score at the start of therapy were applied, which
were found non-significant (p = 0.538 and p = 0.930, re-
spectively). By multivariable analysis, independent pre-
dictors of 28-day mortality in the CytoSorb group were
older age (OR per 10 years older 1.67, 95%CI 1.00–2.70,
p = 0.034), higher levels of lactate at the start of therapy
(OR 1.15, 95%CI 1.01–1.30, p = 0.031) and pneumosepsis
(OR 5.47, 95%CI 1.19–25.19, p = 0.029). Other factors
were not independently associated with mortality
(Table 2).
Discussion
In this investigator-initiated retrospective study, we have
shown for the first time that CytoSorb therapy may im-
prove the 28-day mortality for patients with septic
shock, compared to CRRT. To our knowledge, this rep-
resents the largest cohort of septic shock patients treated
with CytoSorb therapy in which mortality was assessed
as a primary outcome. The observed mortality rate for
CytoSorb therapy was significantly below the predicted
Patients treated with CRRT 
+/- CytoSorb
N=210
CytoSorb
N=101
CRRT only
N=109
Exclusions (N=60)
- CRRT for renal failure (no sepsis) N=44
- Malignancy N=8
- OHCA N=6
- Rhabdomyolysis N=1
- Treatment elsewhere N=1
Exclusions (N=34)
- Malignancy N=25
- OHCA N=2
- Rhabdomyolysis N=3
- Treatment elsewhere N=4
Analyzed
for 28-day mortality
N=67
Analyzed
for 28-day mortality
N=49
Inverse probability of treatment 
weights (IPTW) incl:
- Age
- Comorbidity
- Surgery vs no surgery
- SOFA at start Rx
- Lactate level at start Rx
- Noradrenalin ug/kg/min at Rx
- Type of sepsis (organ)
Fig. 1 Patient and analysis flowchart
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risk of death according to the SOFA score [21, 22]. For
CytoSorb, factors associated with a higher chance of 28-
day mortality were older age, higher lactate levels at the
start of therapy and pneumosepsis.
In the current study, it was investigated whether Cyto-
Sorb improves survival when compared to CRRT alone
in an IPTW analysis. Per protocol, patients were only
treated with CytoSorb in case of septic shock, at the dis-
cretion of the treating intensive care physician. As a
result, it was found that at the start of therapy, patients
treated with CytoSorb had a worse septic shock than
those treated with CRRT alone as shown by higher lac-
tate and noradrenaline levels, and lower mean arterial
blood pressure. Despite that CytoSorb-treated patients
had a worse shock, in an unbalanced analysis, the mor-
tality rate was comparable to patients treated with CRRT
alone. However, it could be argued that patients treated
with CRRT alone were older with more comorbidities
Table 1 Patient characteristics (at ICU admission and at the start of CytoSorb or CRRT)
Characteristics CytoSorb (N = 67) CRRT only (n = 48) Unadjusted p value sIPTW-adjusted p value
Demography
Age, years (Mean, SD) 61.1 (14.7) 68.7 (9.6) 0.001 0.126
Male, n (%) 37 (55%) 30 (61%) 0.522 0.021
Comorbidity, n (%)
Any comorbidity 43 (64%) 42 (88%) 0.002 0.601
Diabetes mellitus type 2 14 (21%) 20 (41%) 0.024 0.778
Hypertension 23 (34%) 26 (53%) 0.046 0.409
Coronary heart disease 9 (13%) 8 (16%) 0.667 0.064
Heart failure (systolic/diastolic) 4 (6%) 10 (20%) 0.030 0.501
Prior chronic kidney disease 8 (12%) 18 (37%) 0.003 0.002
Peripheral artery disease 10 (15%) 8 (16%) 0.839 0.021
Cerebrovascular accident 6 (9%) 3 (6%) 0.577 0.369
COPD 8 (12%) 10 (20%) 0.233 0.002
Primary diagnosis, n (%)
Abdominal sepsis 31 (46%) 12 (25%) 0.014 0.870
Pneumosepsis 14 (21%) 21 (43%) 0.014 0.275
Urosepsis 2 (3%) 6 (12%) 0.078 0.217
Cutaneous/arthritis 9 (13%) 3 (6%) 0.182 0.064
Vascular sepsis 5 (8%) 0 0.024 0.026
Cerebral sepsis 0 1 (2%) 0.322 0.475
Sepsis (unknown cause) 6 (9%) 6 (12%) 0.569 0.755
Admission
Surgical (otherwise medical) 27 (40%) 6 (12%) < 0.001 0.994
Days on ICU 9 (2–19) 9 (3–13) 0.783 0.463
Hemodynamics (Mean, SD)
Lactate at admission 6.4 (5.1) 4.4 (4.4) 0.027 0.421
Lactate at the start of therapy 6.9 (5.6) 2.9 (3.1) < 0.001 0.544
Noradrenaline (μg/kg/min) adm. 0.48 (0.55) 0.29 (0.40) 0.052 0.073
Noradrenaline (μg/kg/min) Rx 0.96 (0.73) 0.28 (0.36) < 0.001 0.769
Total duration noradrenaline (days) 3 (1–5) 3 (1–5) 0.979 0.222
Duration noradrenaline from Rx (days) 2 (1–3) 1 (0–2) 0.694 0.989
MAP at admission 73 (19) 74 (20) 0.748 0.418
MAP at the start of therapy 69 (15) 77 (18) 0.007 0.019
Prognostic scores
SOFA ICU admission 11.7 (3.3) 11.8 (3.5) 0.907 0.854
SOFA at the start of treatment 13.8 (2.8) 12.8 (3.2) 0.067 0.239
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and more often having non-surgical sepsis. Therefore,
observed versus predicted mortality rates were analysed
within treatment groups. This analysis showed that the
mortality rates in this study were lower than that pre-
dicted by the SOFA score at the start of therapy [21].
The results of our study are in line with a previous pro-
spective study in 20 patients with septic shock treated
with CytoSorb, where a 28-day mortality rate of 45% was
reported as well [20].
It is important to investigate factors which are associ-
ated with survival for CytoSorb treatment. For the
current cohort, next to older age, we found that higher
lactate levels at baseline of CytoSorb therapy were asso-
ciated with a worse outcome. Indeed, these factors are
components of the SOFA score itself. Apparently, par-
ticularly the measures of the hemodynamic components
of the SOFA score showed the strongest association with
outcome. Hence, it seems reasonable to assume that
CytoSorb therapy should be initiated as early as possible
in the disease course. Nonetheless, 8 (12%) patients re-
ceived CytoSorb at least 1 day after CRRT was already
started. We performed a sensitivity analysis in which we
excluded these patients and found no deviations from
the main results.
In our cohort, it was found that CytoSorb therapy did
not seem to provide with a survival benefit for patients
with pneumosepsis. This may in part be due to com-
bined difficulties in adequate ventilation and/or presence
of ALI or ARDS in these severely ill patients. These find-
ings are underlined by a recent randomized trial which
assessed IL-6 levels as a primary outcome in patients
with ALI and ARDS and found no survival benefit in
CytoSorb CRRT
28
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Predicted (SOFA)
47.8%
(95%CI: 35.7 – 59.8) 
p=0.035
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(95%CI: 36.9 – 65.2) 
67.9%
(95%CI: 60.7 – 75.2) 
p<0.001
74.5%
(95%CI: 70.7 – 79.0) 
-26.8% (95%CI: -38.2 – -15.3) 
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Fig. 2 a Observed versus predicted mortality rate according to the SOFA score for CytoSorb- and CRRT-treated patients. b CytoSorb is associated
with a reduced 28-day mortality in sIPTW analysis
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these patients as a secondary (but not powered for) out-
come measure [11].
Since the current study is a retrospective data analysis,
there is inherent bias to take into account. Importantly,
by applying IPTW, confounding by indication was as
much as possible eradicated [24]. Still, chance of residual
confounding remains, and some variables were imbal-
anced at the start of therapy. Only MAP was associated
with the primary endpoint, which was accounted for by
multivariable analysis. Moreover, the precise amount of
fluid balances and ultrafiltration rates were not available
for both treatment groups, which was complicated
because this would need a dynamic statistical analysis.
Indeed, fluid balances may be important measures as
several studies show an association with more positive
fluid balances and mortality [26, 27], but there are also
controversial findings with studies showing an associ-
ation between higher fluid balance and improved sur-
vival [28, 29], and even no differences in early goal-
directed therapy [30–32]. It should be underlined that it
is uncertain whether the association between a positive
fluid balance and mortality is a true dose-response
causal relationship. Even though the omission of data on
the fluid balance may be a limitation of the study, both
Table 2 Regression analysis for mortality at 28 days for CytoSorb-treated patients
Variables Univariable Full multivariable model (forced) Final multivariable model (bstep LR)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age per 10 years older 1.99 (1.3–3.1) 0.002 1.64 (1.0–2.7) 0.050 1.67 (1.0–2.7) 0.034
Female gender 1.50 (0.6–4.0) 0.412 – –
Body mass index 0.96 (0.9–1.0) 0.260 – –
SOFA admission 1.20 (1.0–1.4) 0.041 – –
SOFA at the start of treatment 1.28 (1.1–1.6) 0.014 1.10 (0.8–1.4) 0.505 –
MAP admission 0.99 (0.9–1.0) 0.460 – –
MAP at the start of treatment 0.96 (0.9–1.0) 0.051 0.99 (1.0–1.03) 0.739 –
Lactate admission 1.07 (0.9–1.2) 0.180 – –
Lactate at the start of treatment 1.16 (1.0–1.3) 0.014 1.13 (1.0–1.3) 0.108 1.15 (1.0–1.3) 0.031
Noradrenaline admission 2.25 (0.8–6.0) 0.106 – –
Noradrenaline treatment 2.60 (1.2–5.9) 0.021 0.98 (0.3–2.8) 0.973 –
Noradrenaline duration 1.02 (0.9–1.2) 0.731 – –
Admission ICU to treatment 0.88 (0.7–1.1) 0.216 – –
Admission hospital to treatment 0.98 (0.9–1.1) 0.675 – –
Surgery 0.37 (0.1–1.0) 0.055 0.43 (0.1–1.6) 0.206 –
Type of sepsis: – – –
Pneumosepsis 3.52 (1.0–12.7) 0.054 2.83 (0.5–16.9) 0.254 5.47 (1.2–25.2) 0.029
Abdominal sepsis 0.51 (0.2–1.3) 0.171 – –
Cutaneous sepsis 0.27 (0.1–1.4) 0.117 – –
Vascular sepsis 4.86 (0.5–46.0) 0.168 – –
Sepsis unknown cause 2.36 (0.4–13.8) 0.343 – –
History of: – – –
Diabetes mellitus 1.61 (0.5–5.3) 0.432 – –
Hypertension 1.31 (0.5–3.6) 0.601 – –
COPD 1.97 (0.4–9.0) 0.380
Coronary artery disease 0.86 (0.2–3.5) 0.831 – –
Heart failure NA 0.999
Chronic kidney disease 1.98 (0.4–9.0) 0.380 – –
Hemodialysis/peritoneal 1.10 (0.1–18.3) 0.949 – –
CVA 1.10 (0.2–5.9) 0.908 – –
Peripheral artery disease 2.99 (0.7–12.7) 0.139 – –
MAP mean arterial pressure, ICU intensive care unit, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident
Statistically significant data are italicized
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groups received exactly the same standard of care fluid
resuscitation protocols since this is a mono-centre study.
On this basis, both groups are not expected to differ
accordingly.
Albeit patients had a severe refractory septic shock
and were treated with CytoSorb as a last -resort, one
may argue that this treatment modality could have po-
tential detrimental effects. One of these effects may be
that CytoSorb could filter out antibiotics leaving patients
exposed to levels below the therapeutic range [33]. In
the current study, we did not have antibiotic levels avail-
able. Nonetheless, there were no observations or indica-
tions of excessive need for antibiotics or persistence of
infections in the CytoSorb group. Moreover, septic
shock originates from a severe host-response derailment
and endotoxinaemia and as such these patients may
benefit more from CytoSorb therapy than antibiotics
alone, which is underlined by the current data. Our data
also shows that CytoSorb leads to a better outcome in
patients with less severe lactataemia. Given possible anti-
biotic filtration, caution is warranted since the positive
effect may be tipped towards a more negative effect if
CytoSorb therapy is initiated too early. Lastly, a recent
pilot study showed positive effects on lactate and procal-
citonin when CytoSorb was used as a stand-alone ther-
apy [34]. We did not have procalcitonin or interleukin
levels available in our study. Future randomized trials
comparing CytoSorb to CRRT should further elucidate
the effect on interleukin, procalcitonin and antibiotic
levels, and what the timing and duration of CytoSorb
therapy should be.
Conclusion
We have shown, to our knowledge, in the largest cohort
of septic shock patients to date, that CytoSorb treatment
may lead to an improved 28-day survival compared to
CRRT alone, both on basis of observed versus predicted
mortality rates as well as by IPTW. The current data
should be further corroborated by randomized clinical
trials.
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